Kevin Kelly described a Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) bispecific T cell engager showing activity in a phase 1 trial in prostate cancer.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
